Stakes enormous as Supreme Court weighs ‘pay-to-delay’ generic drug deals

From international law firm Arnold & Porter LLP comes timely views on current regulatory and legislative topics that weigh on the minds of today’s physicians and health care executives.The Supreme Court is poised to resolve a long-running debate regarding the legality of so-called “reverse payment” patent litigation settlements between brand drug and generic drug companies. The court heard oral argument on March 25 in FTC v. Actavis, a case that focuses on these settlements, in which (1) the brand company licenses the generic product to enter the market on a (Read more...)

Full Story →